BioSpace News Archive

Renalytix announced that KidneyIntelX™ successfully risk-stratified adult patients with type 2 diabetes and early-stage chronic kidney disease for key clinical outcomes, including heart failure hospitalizations and death.

Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of a U.S. patent (number 11,353,450) for their new innovative and quantitative test system.

Xalud Therapeutics, a clinical-stage biotechnology company developing novel non-viral gene therapies to treat pathologic inflammation, announced today that Chief Executive Officer Diem Nguyen, Ph.D., MBA, will participate in two panels at the BIO International Convention.

Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced the initiation of a Phase 1b trial of its investigational next-generation, highly potent core inhibitor ABI-H3733 (3733).

Corcept Therapeutics Incorporated announced that, following consultation with the U.S. Food and Drug Administration, it will start a registrational Phase 3 trial of relacorilant plus nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer.

Applied Genetic Technologies Corporation (Nasdaq: AGTC), today announced an encore presentation of interim data from its ongoing Phase 2 Skyline trial of AGTC-501, a recombinant AAV viral vector-based gene therapy targeting mutations in the RPGR gene in patients with X-linked retinitis pigmentosa (XLRP), at the 45th Macula Society Annual Meeting.

Portage Biotech Inc. announced that the Company presented early data from its Phase 1/2 study of PORT-2, an invariant natural killer T cell agonist for patients with melanoma and non-small cell lung cancer, at the 2022 American Society of Clinical Oncology meeting.

IO Biotech announced that the company will be participating at the 2022 BIO International Convention, taking place June 13 – 16, 2022, at the San Diego Convention Center in San Diego, California.

Aligos Therapeutics, Inc. (Nasdaq: ALGS), today announced that the company will participate in the newly formed Metropolitan AntiViral Drug Accelerator (MAVDA) which was recently awarded a three-year, $65,141,731 grant from the National Institutes of Health (NIH) and the National Institute of Allergy and Infectious Disease (NIAID)’s Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern program.

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in a panel discussion and deliver a company presentation during the 2022 BIO International Convention being held from June 13-16, 2022 at the San Diego Convention Center.